Trial site
Santo André
Santo André, São Paulo 09060-650, BrazilNot linked to an institution yet
- 11running trials
- 3closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Completed3 trials
- Recruiting3 trials
- Lead sponsor
- Novartis Pharmaceuticals14 trials
Running trials
Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error